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ABSTRACT
Introduction: Rhabdomyosarcoma (RMS) management
depends on risk stratification at diagnosis and treatment
response. Assessment methods include CT, MRI, bone
scintigraphy, histological analysis and bone marrow
biopsy. Advanced functional imaging (FI) has potential to
improve staging accuracy and management strategies.
Methods and analysis:We conducted a systematic
review (PROSPERO 2013:CRD42013006128) of
diagnostic accuracy and clinical effectiveness of FI in
histologically proven paediatric RMS. PRISMA guidance
was followed. We searched 10 databases to November
2013. Studies with ≥10 patients with RMS which
compared positron emission tomography (PET), PET-CT
or diffusion-weighted imaging (DWI) MRI to
conventional imaging at any treatment stage were
included. Study quality was assessed. Limited,
heterogeneous effectiveness data required narrative
synthesis, illustrated by plotting sensitivity and specificity
in receiver operating curve (ROC) space.
Results: Eight studies (six PET-CT, two PET) with 272
RMS patients in total were included. No DWI-MRI studies
met inclusion criteria. Pooled estimates were not
calculated due to sparseness of data. Limited evidence
indicated initial PET-CT results were predictive of
survival. PET-CT changed management of 7/40 patients.
Nodal involvement PET-CT: sensitivity ranged from 80%
to 100%; specificity from 89% to 100%. Distant
metastatic involvement: PET-CT sensitivity ranged from
95% to 100%; specificity from 80% to100%. Data on
metastases in different sites were sparse. Limited data
were found on outcome prediction by PET-CT response.
Dissemination and ethics: PET/PET-CT may increase
initial staging accuracy in paediatric RMS, specifically in
the detection of nodal involvement and distant metastatic
spread. There is a need to further assess PET-CT for this
population, ideally in a representative, unbiased and
transparently selected cohort of patients.
BACKGROUND
Rhabdomyosarcoma (RMS) accounts for over
50% of sarcomas in children and young
people.1 2 Incidence is 4.6 per million aged
<20 years. RMS frequently presents as a soft-
tissue mass. The commonest sites of origin
are head and neck, genitourinary tract, and
limbs. Treatment is based on a multimodality
approach including neoadjuvant chemother-
apy, surgery where possible, radiotherapy and
adjuvant chemotherapy. Overall outcomes
have improved but remain suboptimal, with
3-year event-free survival (EFS) rates for
patients with localised disease of around 60%
in Europe and a corresponding overall survival
(OS) of 80%.3 4 Patients who present with
metastatic disease have much poorer progno-
ses and should be considered for novel treat-
ment strategies. Correct staging is imperative.
Current treatment protocols rest on deci-
sions at several points during therapy. Full
initial staging employs cross-sectional imaging
of the primary tumour (often with MRI);
further cross-sectional imaging of the chest,
abdomen and pelvis; a radiolabelled bone
scan; and pelvic bone marrow biopsies. These
methods are also used to assess disease
Strengths and limitations of this study
▪ This is the first systematic review of the use of
advanced functional imaging in the management
of rhabdomyosarcoma (RMS) in children and
young people.
▪ No studies of diffusion-weighted imaging-MRI in
managing rhabdomyosarcoma of sufficient quality
for inclusion were identified.
▪ Rigorous methodology identified the limitations of
the existing research supporting this use of posi-
tron emission tomography (PET)/PET-CT in the
staging, prognosis development and outcome
assessment of diagnosed RMS.
▪ Paucity of evidence prevented meta-analysis of
sensitivity and specificity and contributed to con-
siderable uncertainty around the true value of
PET-CT, including whether it should be considered
as an additional or a replacement diagnostic tool.
▪ Potential benefits of PET-CT in increasing staging
accuracy were identified: specifically identification
of nodal involvement and metastatic spread. Clear
research recommendations for incorporation of
PET-CT into future treatment trials are presented.
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response for treatment modiﬁcation and at the end of
treatment as ongoing surveillance.3 The usefulness of
assessment methods is under ongoing evaluation; a recent
European paediatric Soft tissue Sarcoma Group (EpSSG)
analysis showed that otherwise low-risk patients are
unlikely to have isolated bone metastasis; in future bone
scans may be omitted for these patients.5 Current assess-
ment methods give discordant results at postchemother-
apy evaluation, highlighting the potential importance of
functional imaging (FI).6
FI has been incorporated into management of other
malignancies (eg, staging non-small-cell lung cancer
(NSCLC) and assessing treatment response in Hodgkin’s
lymphoma) after extensive reviews found strong evidence
for positron emission tomography (PET)-CT.7 It was
found to be cost-effective for assessment of recurrent
colorectal cancer,8 but was less useful than non-nuclear
technologies (eg, functional MRI and nodal biopsies) in
regional node evaluation in breast cancer.9 Previous sys-
tematic reviews with meta-analysis of sarcomas generally
have found uncertain and heterogeneous results.10 11
This is the ﬁrst systematic review of FI in children and
young people with RMS diagnosis. FI has potential as an
additional imaging technique or replacement for current
imaging modalities for initial staging and/or response
assessment.
OBJECTIVE
To assess the role of FI (PET/PET-CT and diffusion-
weighted imaging (DWI)-MRI) in the management of
RMS in childhood and adolescence and to consider its
potential as a tool for improving both diagnostic (staging)
and prognostic evaluation. Assessment of FI for treatment
response and end of treatment evaluations were secondary
aims. The review was not designed to assess the differential
diagnosis of RMS in patients with suspected sarcoma.
METHODS
We undertook a systematic review of the diagnostic
accuracy and clinical effectiveness of PET, PET-CT and
DWI-MRI for assessment of histologically proven RMS in
children and young people. The protocol was registered
on PROSPERO (2013:CRD42013006128)12 and PRISMA
guidance adhered to. We consulted three public patient
(PPI) representatives while writing the protocol and they
contributed to the selection of outcomes assessed.
We searched 10 databases (including MEDLINE,
EMBASE and Cochrane Central Register of Controlled
Trials) from inception to November 2013 without restric-
tions on publication status, date or language (see online
supplementary appendix 1 for full list of databases and
complete search strategies).
The following prespeciﬁed inclusion criteria were applied:
▸ Participants: Children and young people aged 0–24
years of age who are diagnosed with histologically
proven RMS of any type. Studies with mixed tumour
types will be included if outcome data for RMS patients
are reported separately for at least one outcome.
Studies with mixed populations of children/young
people and adults were included where it was clear that
a majority of patients were children/young people.
▸ Interventions: FI: PET±CT, or DWI-MRI used at any
point in the management of RMS.
▸ Comparator: Conventional imaging (one or more of
contrast-enhanced CT or standard MRI, technetium-
99m bone scintigraphy).
▸ Primary outcome: EFS or OS at any time point.
▸ Secondary outcomes: Relapse rates, quality of life, adverse
events or acceptability of the technology (by patient,
carer or health professional), histological conﬁrm-
ation via lesional biopsy, or independent imaging or
comparative classiﬁcation of staging and risk classiﬁca-
tion of disease and treatment alteration in the light of
imaging tests performed.
▸ Study design: Prospective and retrospective studies of
any design with at least 10 patients with RMS for
whom separate data are available for at least one
outcome (following a protocol amendment due to
lack of data; originally studies were required to
include ≥20 patients with RMS).
Studies were assessed for inclusion and appraised for
quality by two independent reviewers. We used a tool
adapted from previous Health Technology Assessment
(HTA) reviews13 14 for quality assessment of case series.
We also assessed the reliability of the processes followed
in carrying out PET and the degree to which accepted
guidelines for the semiquantiﬁcation using standardised
uptake values were followed.15
Data were extracted onto a prespeciﬁed form using the
package EPPI-Reviewer 4 from the UK EPPI-Centre by one
researcher and checked by a second (forms were piloted
by two independent researchers). A third researcher was
consulted where necessary. Patient-level data were
extracted to enable construction of 2×2 tables for detec-
tion of nodal involvement and distant metastases.
Sensitivity and speciﬁcity of PETand conventional imaging
were calculated for each study and plotted in receiver
operating curve (ROC) space using the METANDI
package in STATA. There were insufﬁcient data to calcu-
late pooled sensitivity and speciﬁcity.
At all stages of the review process, we attempted to
contact study authors about uncertain, missing or incom-
plete data.
Owing to the limited and incomplete nature of the
data reported, data at the level of individual primary,
nodal or metastatic sites were summarised in a narrative
synthesis. Data on survival, tumour response and treat-
ment modiﬁcation were very limited and heterogeneous
so were also summarised narratively.
RESULTS
Quantity and quality of evidence
We identiﬁed 1725 unique records and assessed 300 as
full-text papers. Six studies of PET-CT16–21 and two of
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PET22 23 were included; these were reported in a total of
15 publications16–30 and the most up-to-date data were
used in the review (see online supplementary appendix
for ﬂow diagram). All studies had a full primary English
publication; in one case, survival data were available only
in abstract.29
Seven studies included only patients with RMS;16–19 21–23
one included a minority of patients with RMS with separ-
ate data.20 Data were reported on a total of 272 patients
with RMS. Two additional studies reported in abstract
included >10 patients with RMS but were excluded as,
despite author contact, we were unable to obtain separate
RMS patient data.31 32 One study reported separate RMS
data only for the subset of patients with a primary tumour
in the extremities and was included because of these
data.20 Three studies included one or more adults aged
≥25 years; these studies were included because it was clear
that the great majority of patients were children/young
people; median ages were 11 and 13 in two studies17 23
and the mean age in the third was 19.8.19
No studies of DWI-MRI met inclusion criteria (even
after protocol amendment from >20 cases to >10 cases);
only studies that assessed it for differential diagnosis with
very few RMS cases were found.33–39 These studies of
DWI are discussed elsewhere.40 A full list of excluded
studies is available on request.
All studies used ﬂudeoxyglucose (ﬂuorodeoxyglucose,
18F) as the radiopharmaceutical for PET. Most studies
reported using all possible conventional imaging techni-
ques as a comparator to PETor PET-CT (see table 2). The
reference (gold) standard (as distinct from the compari-
son with conventional imaging) was typically a mixture of
histopathology, clinical examination and follow-up.
Included studies often involved more children with
unfavourable prognoses than would be expected in clin-
ical practice: 52% of the patients in the series had an
unfavourable, alveolar histology compared with 20–30%
in clinical practice.1 Histology was generally not well
described and information on genetic predispositions
was limited to one study which noted that no patient had
a history of familial cancer syndrome.21 Where reported,
large numbers of patients had stage III or IV disease com-
pared with around 15% with stage IV disease in clinical
practice.41 Several studies included higher numbers of
patients with primary tumours of the extremities. Study
characteristics are summarised in table 1.
All studies were opportunistic case series. Most were retro-
spective and did not comprise consecutive series of patients.
It was often unclear how representative of the eligible popu-
lation the included patients were. Details of FI procedures
were often not reported. See online supplementary appen-
dix 2 for a summary of quality assessment results. Outcome
reporting was inconsistent and often incomplete. In some
cases this was remedied by contacting authors.
Survival and related outcomes
Only one study (N=41) reported data on OS.22 This found
that metabolic activity of the primary tumour on PET-CT
had prognostic signiﬁcance for survival (p=0.007). Also
predictive of survival were PET-CT detection of nodal
involvement (p=0.016), PET-CT detection of metastases
(p=0.002) and a composite outcome (PET group;
p=0.002). Dichotomisation around the point SUVmax/
SUVliver=4.6 was also predictive (p=0.002). Nodal and
metastatic involvement retained statistical signiﬁcance in a
multivariate analysis; primary tumour intensity did not.
Three studies reported data on EFS.17 22 29 One (N=41)
found similar results for EFS as for OS, with prognostic sig-
niﬁcance for primary tumour intensity (p=0.005), lymph
node detection (p=0.008) and metastases detection
(p=0.01). Dichotomisation around the point SUVmax/
SUVliver=4.6 did not predict EFS.
22 Another study (N=94)
reported trends towards prognostic signiﬁcance for
PET-CT results dichotomised by SUVmax=7.0 at initial
staging (p=0.08) and by pre-radiotherapy (RT) PET-CT-
positivity (after median 15 weeks chemotherapy;
p=0.06).17 At post-RT assessment PET-CT-negative patients
were signiﬁcantly less likely to relapse than PET-positive
individuals (p=0.02). The third study (N=38), available as
an abstract, reported no prognostic signiﬁcance of PET-CT
at any point.29 None of these reports demonstrated an
additional prognostic value of metabolic activity indices
above conventional prognostic criteria.
One study reported tumour response.16 In a subset of
13 patients PET-CT was more likely than conventional
imaging to show complete response to treatment; most
of these patients were assessed by conventional imaging
as having a partial response and 12 were in remission at
follow-up.
Treatment alteration
PET-CT changed the management or treatment course of
7/40 patients in studies that reported this outcome.16 20 21
Quality of life and acceptability
There were no data on quality of life or acceptability of
the technology. All three PPI representatives considered
that additional scans (and their associated requirements
of time, travel and additional procedures) were worth-
while if they could provide additional information to
inform the treatment plan and/or prognosis.
Diagnostic data
Lymph nodes
For nodal involvement, PET-CT or PET showed sensitivity
of 80% (one study)18 or 100% (three studies)19–21 and
speciﬁcity of 89–100% at the patient level. This is com-
pared to sensitivity of between 67% and 86% and speciﬁ-
city of 90% or 100% for conventional imaging (table 2
and ﬁgure 1). The ROC space ‘cross-hairs’ plots show
each study’s estimates of sensitivity and speciﬁcity as a
marker at the point estimate, with 95% CIs demon-
strated by lines. In reading such graphs, tests with better
discriminatory ability fall in the top left corner of the
plot, and non-discriminatory tests fall on a 45° line
between the bottom left and top right.42
Norman G, et al. BMJ Open 2015;5:e006030. doi:10.1136/bmjopen-2014-006030 3
Open Access
 o
n
 22 N
ovem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2014-006030 on 8 January 2015. Downloaded from 
Table 1 Participant characteristics
Study
Intervention
[Conventional imaging methods]
(Reference standard)
N (%
male)
Age (years): mean/
median (range)
Primary tumour location
Histology (%)
Tumour
stage (%)
Risk
classification
(%)Orbit
HN
(nPM)
HN
(PM) Trunk Extremity
GU
(nBP)
GU
(BP) Other
Baum et al22
Germany
PET-CT (whole body)
5 patients received PET only.
[MRI, ultrasound, contrast-enhanced CT]
(clinical diagnosis including CT)
41 (58) 9.9* (1–20) 2 5 2 0 19 2 3 8 Alveolar 24
(59)
Embryonal 17
(41)
NR Group 1 0
Group 2 11 (27)
Group 3 18 (44)
Group 4 12 (29)
Dharmarajan
et al17
USA
PET-CT (coverage NR) Minority had no CT
available. [CT] (NR)
94 (50) 11† (0.2–43) 5 3 34 19 21 3 9 0 Alveolar 44
(47)
Embryonal 49
(52)
Other 1 (1)
Stage I 10
(11)
Stage II 4 (4)
Stage III 48
(51)
Stage IV 32
(34)
Group 1:0
Group 2: 9 (10)
Group 3:53 (56)
Group 4:32 (34)
Eugene et al16
France
PET-CT (whole body)
[Bone marrow biopsy, chest radiograph, CT,
MRI, bone scintigraphy]
(Clinical examination, histopathology,
follow-up, US)
23 (70) 8.7†(0.75–21.6) 5 3 4 0 1 1 4 4 Alveolar 9 (39)
Embryonal 13
(61)
Other 1 (0)
NR NR
Federico
et al18 USA
PET-CT
(Vertex to toes)
[Chest CT, CT/MRI of primary and
local-regional nodal basin, bone scan]
(Clinical assessment, histology)
30 (57) 7.3† (1.3–23.5) 0 4 8 4 9 0 3 2 Alveolar 11
(37)
Embryonal 14
(47)
Other 5 (16)
NR Unclear
Klem et al23
USA
PET (vertex to upper thigh, lower extremities
depending on tumour location and clinical
suspicion)
[CT, MRI or bone scan]
(Imaging, pathology, clinical findings at
tumour board)
24 (42) 13† (1.3–56) 0 3 11 4 4 0 2 0 Alveolar 14
(58),
Embryonal 10
(42)
Stage I 2 (8)
Stage II 2 (8)
Stage III 18
(75)
Stage IV 5
(21)
Group 1 0
Group 2 1 (4)
Group 3 18 (75)
Group 4 5 (21)
Ricard et al21
France
PET-CT (head to upper thigh (4 patients had
scans including legs))
[MRI, CT (primary), bone scintigraphy
(metastases)]
(Histopathology and clinical evaluation at
tumour board)
13 (92) 9.6† (1.8–19.1) 0 4 2 0 0 0 3 4 Alveolar 10
(77),
Embryonal 3
(23)
Stage I 4
(31)
Stage II 1 (8)
Stage III 2
(15)
Stage IV 6
(46)
NR
Tateishi et al19
Japan
PET-CT (head to mid-thigh (2 patients had
scans including legs))
[Chest radiograph, whole body CT, MRI
(primary), bone scintigraphy]
(Histopathology, clinical follow-up, CSF
evaluation)
35 (69) 19.8* (3–38) 1 0 18 8 8 0 0 0 Alveolar 22
(63),
Embryonal 12
(34)
Other 1 (3)
Stage I:
initial 3 (13)
restage 7
(70)
Stage II:
initial 21 (87)
restage 3
(30)
NR
Volker et al20
Germany
PET (whole body)
[Radiography (primary), chest X-ray, CT, MRI
(primary and additional regions where
clinically indicated), US (abdominal and
additional regions where clinically indicated),
bone scintigraphy]
(Histopathology, clinical examination including
follow-up)
46 (52)‡ 12.9* (1–18)‡ NR NR NR NR
*Mean.
†Median.
‡Whole group (data not available for patients only with RMS).
BP, bladder/prostate; GU, genitourinary; HN, head and neck; nBP, non-bladder/prostate; NR, not reported; nPM, non-parameningeal; PM, parameningeal; RMS, rhabdomyosarcoma.
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Nodal level data from three studies also indicated that
PET-CT was able to detect more positive nodes than con-
ventional imaging with very few false positives.16 18 21
One study with fully reported data found sensitivity
and speciﬁcity of 100% for PET-CT compared with 75%
and 94% for conventional imaging.16 Where reported,
PET-CT generated many fewer indeterminate results
(1 vs 18/35) and more true negatives than conventional
imaging.18
Distant metastases
For detection of distant metastatic sites, PET-CT had a
sensitivity of 95% (1 study)19 or 100% (2 studies)18 21
and speciﬁcity of 80–100% at the patient level. This is
compared to sensitivity of between 17% and 83% and
speciﬁcity of between 43% and 100% for conventional
imaging (table 2 and ﬁgure 2).
Site level data from another study also found higher sen-
sitivity and speciﬁcity (100% and 96%) for PET-CT com-
pared with 66% and 91% for conventional imaging.16
Information on detection of metastases in different
sites was extremely limited and reported at the level of
individual cases (table 3).16 18 19 21 There were indica-
tions from this very limited evidence base that PET-CT
may be superior to CI for detection of bone lesions, in
that both additional lesions and patients with otherwise
undetectable bone involvement were identiﬁed.16 18 19 21
The number of false positives was low. PET-CT may also
have potential to speciﬁcally identify marrow involve-
ment in some patients but this ﬁnding is unclear and
based on tiny numbers of patients; sensitivity appeared
limited.18 PET-CT appeared poor for detection of lung
metastases.18 21 There were indications that PET-CT may
perform better than conventional imaging in detecting
soft-tissue lesions in non-pulmonary locations,18 19 pos-
sibly including distal nodal involvement.21
Table 2 Summary of patient-level diagnostic data: detection of nodal and distant metastatic involvement
Study Image N
Sensitivity Specificity
PET Conventional imaging PET Conventional imaging
Nodal involvement
Federico et al18 PET-CT 30 0.8 – 1 –
Ricard et al26 PET-CT 13 1 0.75 0.89 1
Tateishi et al19 PET-CT 35 1 0.86 0.95 0.9
Volker et al20 PET 4* 1 0.67 1 1
Distant metastatic involvement
Federico et al18 PET-CT 30 1 0.17 0.92 1
Ricard et al26 PET-CT 13 1 0.83 1 0.86
Tateishi et al19 PET-CT 35 0.95 0.55 0.8 0.43
*Total N=46; 12 RMS; data available on 4 with extremity primary tumour.
PET, positron emission tomography; RMS, rhabdomyosarcoma.
Figure 1 Sensitivity and specificity of positron emission
tomography-CT versus conventional imaging in detection of
nodal involvement plotted in ROC space.
Figure 2 Sensitivity and specificity of positron emission
tomography (PET)-CT versus conventional imaging in detection
of distant metastatic involvement plotted in ROC space.
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Primary tumours
The ability of PET-CT to detect primary tumours was
good; only one known tumour site was missed16 and one
previously occult primary was identiﬁed21; further details
are in online supplementary appendix 3.
DISCUSSION
We identiﬁed eight studies (272 patients) of PET or
PET-CT in children and young people with RMS and no
eligible studies of DWI-MRI.
The studies identiﬁed had multiple limitations. All
studies were opportunistic case series open to a range of
biases. As such they addressed multiple aspects of the use
of PET in RMS management. Patients already had a diag-
nosis of RMS, so the studies were not diagnostic in the con-
ventional sense; rather they were concerned with accuracy
of staging, determination of prognosis and, in some cases,
evaluation of treatment outcome. The review was not
designed to assess the value of PET-CT in imaging primary
tumours, as the requirement for histologically proven RMS
diagnosis meant that almost all patients had a known
tumour site. This makes comparison to earlier reviews that
included all sarcomas unhelpful.10
The studies included a higher proportion of more chal-
lenging cases than expected in clinical practice. Imaging
methodology was not well reported. Duplicate blinded
evaluation of the FI results relative to the conventional
imaging results or reference standard was often absent or
unclear. Results were often not clearly or fully reported
and data remained inconsistent and incomplete even after
contacting authors. Our ﬁndings are therefore tentative
and require conﬁrmation by further research.
PET-CT was consistently somewhat better than conven-
tional imaging at identifying patients with nodal involve-
ment at initial staging and was clearly more sensitive to
individual positive nodes, with fewer indeterminate
results. PET-CT appeared to improve sensitivity in identi-
ﬁcation of distant metastases including identifying
patients in whom distal metastatic involvement was not
otherwise indicated. There is a suggestion of a role for
PET-CT in detection of bone involvement but a great
deal of uncertainty. Data for lung lesions are sparse and
do not suggest utility. These results accord with reviews
of PET-CT in staging of osteosarcoma43 and PET in
general diagnosis of pulmonary nodules.44
There is very limited evidence on use of PET-CT for
treatment response and end of treatment evaluation. Only
three studies investigated the primary outcome of survival
and one evaluated tumour response. PET-CT at initial
staging may have predictive value for OS and EFS. The
role of PET-CT in the assessment of treatment response
before and after radiotherapy is unclear. PET-CT may be
superior at ascertaining complete response to chemother-
apy but this is based on one small study. The tentative ﬁnd-
ings of this review suggest that the performance of PET-CT
in RMS may be closer to that in Hodgkin’s lymphoma,
NSCLC7 and colorectal cancer8 than in breast cancer.9
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None of the studies reported data on the impact of FI
or conventional imaging on quality of life or acceptability
to any identiﬁed stakeholder group. Our PPI representa-
tives indicated that potential additional information was
highly valued and mattered more than a need for add-
itional procedures and the resource implications of add-
itional scans. They were particularly supportive of FI in
further research with potential to clarify possible beneﬁts
of additional or alternative imaging procedures.
This systematic review represents the ﬁrst thorough
evaluation of the international evidence on FI in the man-
agement of childhood and adolescent RMS. Extensive
searching without language restrictions ensured the inclu-
sion of all relevant studies. We made substantial efforts to
obtain supplementary data from authors. Although some
studies contained patients aged >24 years, we are conﬁ-
dent from the mean/median ages reported that these
were a small minority of the populations and that the rele-
vance of the studies to the paediatric population was not
signiﬁcantly impacted. Excluding these studies would have
resulted in the loss of data on a signiﬁcant proportion of
documented PET use in paediatric RMS. Studies were
quality assessed and synthesised to provide an unbiased
comprehensive assessment of the evidence.
The key limitation was our inability to obtain all relevant
data despite contacting authors. In particular we are aware
of two case series in sarcoma patients which included >10
patients with RMS that we could not include as authors
were unable to provide separate data on RMS cases. The
lack of complete patient-level data from all included studies
meant we were unable to calculate pooled estimates for the
sensitivity and speciﬁcity of FI and conventional imaging.
However, even had we acquired full data on all known
patients with paediatric RMS, the total number would have
remained under 300. Any answers to the review questions
would have remained tentative and uncertain. There is an
urgent need for more reliable disease assessment at all
stages of RMS management. PET-CT may be an option for
this with sufﬁcient prospective testing through incorpor-
ation into any future trials of RMS treatments.
CONCLUSION
This review highlights potential from PET-CT in imaging
of children and adolescents with RMS but there is a high
level of uncertainty in these data and their relevance to
clinical practice. Limited evidence suggests that PET/
PET-CT has potential to increase initial staging accuracy,
speciﬁcally detection of nodal involvement and distant
metastatic spread. There is little evidence on the impact of
PET-CT in assessment of therapeutic response or post-
treatment assessment. The ultimate impact of FI with
PET-CT on treatment outcomes could not be addressed
and it remains unclear whether and how increasing accur-
acy at initial staging might alter patient management and
survival. It was impossible to determine whether PET-CT
could replace any current imaging tests or should be used
as an adjunct.
DWI-MRI has been insufﬁciently researched to answer
questions of utility in RMS; the very limited evidence
base for this is discussed elsewhere.40
RECOMMENDATIONS FOR FURTHER RESEARCH
▸ A representative, unbiased and transparently selected
cohort of patients (entering a treatment randomised
controlled trial (RCT)) should be identiﬁed. All patients
should be evaluated using PET-CT as an adjunct to con-
ventional techniques at initial staging, treatment
response and end of treatment.
▸ The protocol should specify interim data analysis,
potentially enabling PET-CT to replace one or more
conventional staging techniques or substantially modify
treatment delivery by response assessment.
▸ Results should be fully reported and individual
patient data made available.
▸ Methodology of the PET-CT process should be standar-
dised and reported fully. This should include independ-
ent reading of scans by multiple assessors blinded to
conventional imaging and clinical/histological results.
▸ Appropriate qualitative methodologies should be
used to assess the additional burden of treatment to
patients and healthcare system, and resource use pro-
spectively evaluated.
▸ Further comparative research on DWI-MRI in RMS is
needed; researchers using this technology in patients
with RMS should be encouraged to publish case
series in the ﬁrst instance.
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